The trial is being supervised by the World Health Organization (WHO).
Nasbi informed that the preclinical, first phase, and second phase of the trial have been completed, and the third phase is currently on.
"Currently, the focus of the test is to see the percentage of participants' recovery, not to test the safety of the vaccine," he said on Saturday.
Nasbi confirmed there have been no reports of negative effects from the vaccine during the trial.
The clinical trial has not involved the general public, but participants who meet the research criteria, especially people with TB, he explained.
Besides the WHO, the trial is being monitored by the Health Ministry, hospitals, and universities, he added.
"Many are monitoring the standardization of the implementation of this clinical trial," he explained.
In addition, Indonesia is participating in the trial to get priority in the production of the vaccine, Nasbi informed.
Related news: Tackling TB crucial for human resource development: PCO
The effort is expected to help Indonesia achieve the target of eliminating TB by 2030, he said.
"This is a disease of less developed countries, while we aim to be a developed country," he added.
Earlier, the Ministry of Health reported that Indonesia had completed the participant recruitment process for the phase 3 clinical trial of the M72 TB vaccine candidate.
As many as 2,095 adolescent and adult participants have joined the global study, which is also being carried out in South Africa, Kenya, Zambia, and Malawi.
Head of the ministry's Communication and Public Information Bureau, Aji Muhawarman, on Thursday informed that the development of the vaccine is being funded by the Gates Foundation.
He confirmed that all M72 vaccine clinical trials in Indonesia have been conducted under the strict supervision of the WHO, Food and Drug Supervisory Agency (BPOM), Ministry of Health, and national and global TB vaccine experts.
Related news: Bill Gates, Prabowo discuss TB vaccine trials in Indonesia
Translator: Fathur Rochman/Pradanna P, Resinta S
Editor: Rahmad Nasution
Copyright © ANTARA 2025
